How to buy United Therapeutics (UTHR) shares in the UK

Learn how to easily invest in United Therapeutics shares.

United Therapeutics Corporation (UTHR) is a publicly traded biotechnology business based in the US. It opened the day at $185.57 after a previous close of $183.98. During the day the price has varied from a low of $185.57 to a high of $188.63. The latest price was $187.65 (25 minute delay). United Therapeutics is listed on the NASDAQ and employs 965 staff. All prices are listed in US Dollars.

How to buy shares in United Therapeutics

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: UTHR in this case.
  5. Research United Therapeutics shares. The platform should provide the latest information available.
  6. Buy your United Therapeutics shares. It's that simple.
The whole process can take as little as 15 minutes. You'll need a smartphone or computer, an internet connection, your passport or driving licence and a means of payment.

Fees for buying 5x United Therapeutics shares with popular platforms

Both exchange rates and share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.

Platform Platform fee Min. initial deposit Trading fee estimate
eToro Free Stocks logo £0 $10 £4.15
£833.37 total
Capital at risk
IG Share Dealing logo £0 £250 £13.03
£842.25 total
Capital at risk
Fineco logo £0 No minimum £8.29
£837.52 total
Capital at risk
Hargreaves Lansdown Fund and Share Account logo £0 £1 £20.24
£849.47 total
Capital at risk
Degiro Share Dealing logo £0 £0.01 £0.83
£830.05 total
Capital at risk
interactive investor Trading Account logo £9.99 per month No minimum £20.43
£849.65 total
Capital at risk
Stake logo £0 £50 £4.15
£833.37 total
Capital at risk
Halifax Share Dealing Account logo £36 per year £20 £19.87
£849.09 total
Capital at risk

Full comparison of share dealing platforms

United Therapeutics share price (NASDAQ:UTHR)

Use our graph to track the performance of UTHR stocks over time.

United Therapeutics price performance over time

Historical closes compared with the last close of $187.65

1 week (2022-09-28) -11.10%
1 month (2022-09-02) -15.82%
3 months (2022-07-05) -20.87%
6 months (2022-04-04) 1.97%
1 year (2021-10-05) -0.58%
2 years (2020-10-05) 77.55%
3 years (2019-10-04) 136.96%
5 years (2017-10-05) 51.39%

Is it a good time to buy United Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page.

Promoted
eToro Free Stocks

Invest in United Therapeutics shares with 0% commission

  • Start investing from as little as $10
  • Pay no stamp duty on UK shares
  • Join 25 million users who trust their investments with eToro
Other fees apply. Capital at risk

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.

Is United Therapeutics under- or over-valued?

Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value.

P/E ratio

United Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 16x. In other words, United Therapeutics shares trade at around 16x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

PEG ratio

United Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.8304. A PEG ratio below 1 can be interpreted as meaning the shares are not overvalued given the current rate of growth.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into United Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

EBITDA

United Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $939.1 million (£830 million).

The EBITDA is a measure of a United Therapeutics's overall financial performance and is widely used to measure a its profitability.

Environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like United Therapeutics.

Total ESG risk score

United Therapeutics's total ESG risk: 35.51

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and United Therapeutics's overall score of 35.51 (as at 01/01/2019) is nothing to write home about – landing it in it in the 54th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like United Therapeutics is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Environmental score

United Therapeutics's environmental score: 6.16/100

United Therapeutics's environmental score of 6.16 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that United Therapeutics is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Social score

United Therapeutics's social score: 24.94/100

United Therapeutics's social score of 24.94 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that United Therapeutics is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Governance score

United Therapeutics's governance score: 17.41/100

United Therapeutics's governance score puts it squarely in the 9th percentile of companies rated in the same sector. That could suggest that United Therapeutics is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Controversy score

United Therapeutics's controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, United Therapeutics scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that United Therapeutics has, for the most part, managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

United Therapeutics Corporation was last rated for ESG on: 2019-01-01.

Total ESG score 35.51
Total ESG percentile 53.55
Environmental score 6.16
Environmental score percentile 9
Social score 24.94
Social score percentile 9
Governance score 17.41
Governance score percentile 9
Level of controversy 2

United Therapeutics shares at a glance

Information last updated 2021-07-09.
Open$185.57
High$188.63
Low$185.57
Close$187.65
Previous close$183.98
Change$3.67
Change %1.9948%
Volume193,123
Information last updated 2022-10-02.
52-week range$158.38 - $245.48
50-day moving average$220.2018
200-day moving average$206.0105
Wall St. target price$248.56
PE ratio15.8741
Dividend yield$0 (0%)
Earnings per share (TTM)$13.19

Do United Therapeutics shares pay dividends?

We're not expecting United Therapeutics to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.

Share price volatility

Over the last 12 months, United Therapeutics's shares have ranged in value from as little as $158.38 up to $245.48. A popular way to gauge a stock's volatility is its "beta".

UTHR.US volatility(beta: 0.54)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while United Therapeutics's is 0.5358. This would suggest that United Therapeutics's shares are less volatile than average (for this exchange).

Frequently asked questions

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site